The following amendment has been made to the 'Issue of Equity' announcement released on 7 August 2018 at 14:46 under RNS No 0970X.
The total voting rights figure was incorrectly stated as 34,052,927. This figure has now been corrected to 34,102,927. All other details remain unchanged.
The full amended text is shown below.
Hydrogen Group plc ("Hydrogen", the "Group")
Issue of Equity
Hydrogen Group, the global specialist recruitment group, announces that is has made has made an application to the London Stock Exchange for the admission to trading on AIM of 50,000 new ordinary shares of 1p each ("New Shares") to satisfy the exercise of options granted under the Group's Enterprise Management Incentive Scheme.
The New Shares are expected to be admitted to trading on AIM on 13 August 2018.
Following this admission, the Group's share capital and total voting rights comprises 34,102,927 ordinary shares of 1p each and the Group does not hold any shares in treasury. Consequently, 34,102,927 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Hydrogen under the FCA's Disclosure and Transparency Rules.
The balance of the options have been granted to certain employees.
Hydrogen Group plc 020 7090 7702
Ian Temple CEO
John Hunter, Managing Director
Shore Capital (NOMAD and Joint Broker) 020 7408 4090
Edward Mansfield / James Thomas
Whitman Howard Limited (Joint Broker) 020 7659 1234
Notes to Editors:
Hydrogen Group's mission is to empower people's careers whilst powering businesses by providing their key people from a proven global platform with clients' in over 50 countries. We deliver by building market leading specialist teams that develop a deep understanding of candidate and clients' needs and developing solutions.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.